Media coverage about Curis (NASDAQ:CRIS) has trended somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Curis earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.6878079825212 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Curis (NASDAQ:CRIS) traded up $0.01 during trading on Thursday, hitting $0.83. 1,314,300 shares of the company traded hands, compared to its average volume of 791,701. The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15. Curis has a 12 month low of $0.79 and a 12 month high of $3.48.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $2.44 million for the quarter, compared to the consensus estimate of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.21) earnings per share. equities research analysts forecast that Curis will post -0.41 EPS for the current year.

Several equities analysts have commented on CRIS shares. Guggenheim started coverage on shares of Curis in a report on Monday, October 23rd. They issued a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research lowered shares of Curis from a “hold” rating to a “sell” rating in a report on Friday, November 10th. ValuEngine lowered shares of Curis from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, BidaskClub raised shares of Curis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 17th. Three equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. Curis presently has an average rating of “Hold” and a consensus price target of $6.50.

In related news, CEO Ali Ph.D. Fattaey purchased 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The shares were bought at an average cost of $1.06 per share, with a total value of $53,000.00. Following the acquisition, the chief executive officer now owns 115,890 shares of the company’s stock, valued at approximately $122,843.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Insider Buying and Selling by Quarter for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with Analyst Ratings Network's FREE daily email newsletter.